Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.31 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.31 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19627711 | 1.00 | SCN8A (0.33) | SCN8AKAT6AKAT5KAT8PTPN22 | |
| SCHEMBL19614123 | 0.85 | PTPN22 (0.37) | PTPN22 | |
| SCHEMBL19631663 | 0.83 | SCN8A (0.32) | SCN8A | |
| SCHEMBL22331230 | 0.82 | SCN8A (0.35) | SCN8A | |
| SCHEMBL36151836 | 0.80 | SCN8A (0.46) | SCN8A | |
| SCHEMBL29447395 | 0.80 | PTPN22 (0.33) | SCN8AKAT6AKAT5KAT8PTPN22 | |
| SCHEMBL326999 | 0.80 | SCN8A (0.46) | SCN8A | |
| SCHEMBL19627669 | 0.80 | PTPN22 (0.33) | SCN8AKAT6AKAT5KAT8PTPN22 | |
| SCHEMBL31018048 | 0.80 | PIK3CD (0.35) | SCN8APIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL21783523 | 0.80 | PIK3CD (0.35) | SCN8APIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | SCN8A 14/4885KAT6A 4434/4885KAT5 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.